An exploratory open‐label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia

Objective:  We conducted this 6‐week open‐label trial to examine the effects of adjunctive aripiprazole in clozapine‐treated subjects on weight, lipid and glucose metabolism, as well as positive and negative symptoms of schizophrenia.

[1]  R. Kerwin,et al.  Amisulpride augmentation of clozapine: an open non‐randomized study in patients with schizophrenia partially responsive to clozapine , 2004, Acta psychiatrica Scandinavica.

[2]  D. Braus,et al.  Differential Effects of Long-Term Treatment with Clozapine or Haloperidol on GABA Transporter Expression , 2004, Pharmacopsychiatry.

[3]  L. Kunkel,et al.  Clozapine and hypertension: a chart review of 82 patients. , 2004, The Journal of clinical psychiatry.

[4]  Paul Ernsberger,et al.  H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs , 2003, Neuropsychopharmacology.

[5]  S. Potkin,et al.  Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. , 2003, Archives of general psychiatry.

[6]  R. Mailman,et al.  Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology , 2003, Neuropsychopharmacology.

[7]  M. Bickerdike.  5-HT2C receptor agonists as potential drugs for the treatment of obesity. , 2003, Current topics in medicinal chemistry.

[8]  Thomas Pollmächer,et al.  Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. , 2003, Journal of psychiatric research.

[9]  D. Allison,et al.  The impact of weight gain on quality of life among persons with schizophrenia. , 2003, Psychiatric services.

[10]  D. Jody,et al.  Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study , 2003, Psychopharmacology.

[11]  J. Lieberman,et al.  Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. , 2003, The American journal of psychiatry.

[12]  J. Kane,et al.  Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. , 2002, The Journal of clinical psychiatry.

[13]  C. Altar,et al.  The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. , 2002, European journal of pharmacology.

[14]  D. Allison,et al.  Antipsychotic-induced weight gain: a review of the literature. , 2001, The Journal of clinical psychiatry.

[15]  S. Zorn,et al.  The pharmacology of weight gain with antipsychotics. , 2001, The Journal of clinical psychiatry.

[16]  D. Allison,et al.  Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate , 2001, Psychiatry Research.

[17]  D. Taylor,et al.  Atypical antipsychotics and hyperglycaemia , 2001, International clinical psychopharmacology.

[18]  M. Millan.  Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. , 2000, The Journal of pharmacology and experimental therapeutics.

[19]  D. Goff,et al.  Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. , 2000, The American journal of psychiatry.

[20]  J. Meyer.  Novel antipsychotics and severe hyperlipidemia , 2000, Schizophrenia Research.

[21]  M. Heo,et al.  Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.

[22]  H. Rosengarten,et al.  The effect of novel antipsychotics in rat oral Dyskinesia , 1999, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[23]  M. Reinstein,et al.  Effect of Clozapine-Quetiapine Combination Therapy on Weight and Glycaemic Control , 1999 .

[24]  L. Tecott,et al.  Reduced satiating effect of d-fenfluramine in serotonin 5-HT2C receptor mutant mice , 1999, Psychopharmacology.

[25]  D. Goff,et al.  Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. , 1996, The Journal of clinical psychiatry.

[26]  Philip Seeman,et al.  Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine , 1996, Neuropsychopharmacology.

[27]  M. First,et al.  The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. , 1992, Archives of general psychiatry.

[28]  G Honigfeld,et al.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.

[29]  A. Kissebah,et al.  Relation of Body Fat Distribution to Metabolic Complications of Obesity , 1982 .

[30]  D. Allison,et al.  Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. , 2005, Archives of general psychiatry.

[31]  M. Denniston,et al.  Measurement of fatigue in cancer patients: Further validation of the Fatigue Symptom Inventory , 2004, Quality of Life Research.

[32]  J. Thome,et al.  Combination of Clozapine and Amisulpride in Treatment-Resistant Schizophrenia - Case Reports and Review of the Literature , 2004, Pharmacopsychiatry.

[33]  K. Adeli,et al.  Mechanisms of metabolic dyslipidemia in insulin resistant states: deregulation of hepatic and intestinal lipoprotein secretion. , 2003, Frontiers in bioscience : a journal and virtual library.

[34]  D. Henderson.  Clinical experience with insulin resistance, diabetic ketoacidosis, and type 2 diabetes mellitus in patients treated with atypical antipsychotic agents. , 2001, The Journal of clinical psychiatry.